Enveric Biosciences Inc. has announced positive preclinical results for its lead drug candidate, EB-003, aimed at treating severe chronic depression and despair. Conducted in the Open Space Forced Swim Test, a recognized animal model for psychiatric behavior, the study demonstrated significant improvements in depression-like behavior in mice. An oral dose of 30 mg/kg of EB-003 was shown to reduce depression-like symptoms within 30 minutes, with results comparable to the effects of the antidepressant Imipramine. Additionally, extended daily administration of EB-003 over 22 days revealed no adverse effects, indicating the compound's safety for long-term use. These findings support Enveric's plans to proceed with an Investigational New Drug application.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.